---
ID: P75
Title: Antimicrobial Stewardship & Resistance Fighter
Registry: CLAI-OS Human Good Systems (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P75: Antimicrobial Stewardship & Resistance Fighter

## Abstract

Antimicrobial resistance (AMR) is both an individual therapeutic challenge and a planetary-scale collective action failure. Every prescription is an ecological event with downstream consequences across hospitals, nations, agriculture, wastewater, and future generations. P75 is a continuously learning antimicrobial governance architecture that constrains inappropriate prescribing, enforces evidence-based duration ceilings, identifies ecological resistance threats, and preserves last-line therapies through real-time clinical adjudication.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

### Clinical Logic

- Empiric therapy adjudication engine calculating multidimensional coverage matrices across infection site, severity, host factors, local resistance, prior exposure, and organ dysfunction.
- Antibiotic time-out enforcement at 48 to 72 hours with mandatory reassessment questions and hard-stop alerts for de-escalation opportunities.
- PK/PD precision layer with beta-lactam time-above-MIC optimization, vancomycin AUC/MIC targeting, and extended infusion protocols adapted to renal clearance, obesity, CRRT, and ECMO.
- Restricted antimicrobial governance (carbapenems, polymyxins, novel beta-lactam combinations) through documented indication, microbiology justification, and automatic de-escalation review.
- Global resistance surveillance via Bayesian antibiogram updating, wastewater epidemiology, agricultural resistance mapping, and machine-learning emergence forecasting.

### Safety Posture

- Ecological Prescription Intelligence weights each antimicrobial decision by posterior resistance probability incorporating regional epidemiology, patient risk factors, recent exposure, and molecular genomics.
- Allergy Delabeling Engine provides risk-stratified penicillin allergy evaluation with direct oral challenge pathways to restore beta-lactam access and reduce carbapenem overuse.
- Planetary AMR Modeling tracks cross-species resistance (human, livestock, aquaculture, wildlife, wastewater) with outbreak trajectory prediction.

### Integration Points

- **Upstream:** P74 (Trauma Architect) for empiric sepsis coverage; P76 (Vaccine Validator) for infection prevention synergy.
- **Downstream:** P86 (One Health Sentinel) for zoonotic AMR tracking; P104 (Cold Chain) for biologic transport integrity.

Like all Tier II modules, this module shares the common CLAI-OS methodological substrate: deterministic safety compilation, context-sensitive adaptation, closed-loop accountability, federated learning via encrypted gradients rather than raw data, and graceful degradation under bandwidth, power, staffing, and infrastructure failure.

## Merits

- Treats every prescription as an ecological event, linking individual adjudication to institutional, agricultural, and wastewater resistance surveillance.
- Proposed validation metrics: days of therapy per 1,000 patient-days, broad-spectrum utilization rate, time-to-appropriate therapy, C. difficile incidence, carbapenem consumption trends, and resistance emergence rate.
- Preserves last-line agents through documented-indication gating and automatic de-escalation review rather than prescriber recall alone.

The merits above are design-level statements drawn from the published abstract and methodology. No peer-reviewed outcome evaluations accompany this release; the listed indicators are the metrics the design proposes for validation. Status: partial documentation — expansion pending.

## Guidance for Use

### Intended Setting

Hospital antimicrobial stewardship programs, microbiology-linked prescribing environments, and regional resistance surveillance networks in low-resource-first deployment, where empiric broad-spectrum prescribing is commonest and antibiogram data thinnest. The module is intended for clinical human-good applications; consistent with the Tier II architecture, it is specified for degraded-infrastructure operation, with offline synchronization, battery operation, SMS fallback, and low-bandwidth mode where power or connectivity is unstable.

### Prerequisites

- Access to local or regional antibiogram data (the Bayesian updating layer is specified to work from sparse data); microbiology laboratory linkage for culture-guided de-escalation.
- Supervision by licensed clinicians who retain final authority for every patient decision; the module is a governance layer, not an autonomous practitioner.
- Local validation of all thresholds and pathways against jurisdictional guidelines, formulary, and scope-of-practice rules before any clinical use.
- An accountability chain (verification, documentation, ownership, follow-up, escalation) as required by the shared CLAI-OS closed-loop methodology.
- For integrated deployments: HL7 FHIR R4-compatible infrastructure; the architecture is specified to degrade gracefully (offline synchronization, battery operation, SMS fallback, low-bandwidth mode) where infrastructure is unstable.

### Misuse

- Do not use restriction logic to withhold indicated empiric therapy in sepsis; the design escalates for time-critical coverage rather than delaying it.
- Do not present module output as a clinical diagnosis, prescription, or substitute for professional judgment.
- Do not use to deny, delay, or ration care on the basis of race, disability, wealth, insurance status, or any protected characteristic; the design explicitly prohibits such inputs.
- Do not attempt to reconstruct or reimplement the withheld prompt body from this document; the abstract and methodology are published for examination and validation, not for unsupervised clinical deployment.
- Do not deploy as an autonomous system that overrides documented patient wishes, assigns futility, initiates withdrawal of care, or delays emergent intervention; the architecture carries hard-stops against each of these.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
